摘要
Objective: To compare the long-term efficacy and safety of bi-matoprost vs timolol in glaucoma/ocular hypertensive patients. Methods: In a 12-month extension of a multicenter, randomized, double-masked, 1 -year, clinical trial, patients were treated with bimatoprost 0.03% QD approximately 8PM (n =167), bimato-prost 0.03% BID (n = 131), or timolol 0.5% BID (n=81). Study visits were scheduled at months 15, 18, 21, and 24 with
出处
《国际眼科杂志》
CAS
2003年第1期68-69,共2页
International Eye Science
